Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

N/A

1(16.7%)

Phase 3

1(16.7%)

Phase 4

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(2)

N/A(1)

Phase 3(1)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02784821Phase 2Completed

Antibiotic "Dysbiosis" in Preterm Infants

Role: collaborator

NCT02091037Completed

S. Aureus Colonization in Atopic Dermatitis

Role: collaborator

NCT02633371Not ApplicableCompleted

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

Role: collaborator

NCT00312520Phase 3Completed

Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy

Role: collaborator

NCT02061735Completed

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

Role: collaborator

NCT00179959Phase 4Completed

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Role: collaborator

NCT01408056Phase 2Withdrawn

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Role: collaborator

NCT01031901Phase 1Completed

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Role: collaborator

NCT00467792Completed

Natural History of Urticaria Pigmentosa in Children

Role: collaborator

All 9 trials loaded